Zhitong Finance App News, Yingpai Pharmaceutical-B (07630.HK) announced that the European Medicines Agency (EMA) Committee on Medicines for Human Use (CHMP) has passed a positive opinion recommending approval of the marketing license (MA) for the drug Sepalna® (Senapali). The drug is intended for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.